The historical rank and industry rank for Prescient Therapeutics's PB Ratio or its related term are showing as below:
FRA:UDD'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 4.25
Current: 4.25
During the past 13 years, Prescient Therapeutics's highest PB Ratio was 4.25. The lowest was 0.00. And the median was 0.00.
FRA:UDD's PB Ratio is ranked worse than 63.19% of 1228
companies
in the Biotechnology industry
Industry Median: 2.97
vs FRA:UDD: 4.25
During the past 12 months, Prescient Therapeutics's average Book Value Per Share Growth Rate was -15.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -18.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -11.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -13.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Prescient Therapeutics was 181.50% per year. The lowest was -74.10% per year. And the median was -18.30% per year.
Back to Basics: PB Ratio
Prescient Therapeutics (FRA:UDD) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Prescient Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prescient Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Prescient Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Prescient Therapeutics (FRA:UDD) has a PB Ratio of 2.07 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Prescient Therapeutics and its competitors. According to the industry distribution chart, Prescient Therapeutics ranks #776 out of 1228 companies in the Biotechnology industry, placing it in the top 63.2%.
Is Prescient Therapeutics' PB Ratio too high?
Prescient Therapeutics' current PB Ratio is 2.07. The Biotechnology industry median PB Ratio is 2.97. Prescient Therapeutics' value of 2.07 is 30.3% below this industry median. Based on the distribution chart, Prescient Therapeutics ranks #776 out of 1228 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Prescient Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Prescient Therapeutics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Prescient Therapeutics ranks #776 out of 1228 companies for PB Ratio. This places Prescient Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.97. Prescient Therapeutics' value of 2.07 is 30.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prescient Therapeutics's current PB Ratio of 2.07 is 30.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Prescient Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prescient Therapeutics's current PB Ratio is 2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (FRA:UDD) has a current PB Ratio of 2.07. The current PB Ratio is 2.07 and 30.3% below the Biotechnology industry median of 2.97. Prescient Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Prescient Therapeutics (FRA:UDD), the current PB Ratio is 2.07 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
22GF Score
Get the complete analysis for FRA:UDD
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UDD has been successfully added to your 
